TR201809050T4 - Sızan afinite arındırma ligandının giderilmesi. - Google Patents

Sızan afinite arındırma ligandının giderilmesi. Download PDF

Info

Publication number
TR201809050T4
TR201809050T4 TR2018/09050T TR201809050T TR201809050T4 TR 201809050 T4 TR201809050 T4 TR 201809050T4 TR 2018/09050 T TR2018/09050 T TR 2018/09050T TR 201809050 T TR201809050 T TR 201809050T TR 201809050 T4 TR201809050 T4 TR 201809050T4
Authority
TR
Turkey
Prior art keywords
protein
nacl
chromatography
condition
recombinant
Prior art date
Application number
TR2018/09050T
Other languages
English (en)
Turkish (tr)
Inventor
Ray Trejo Samuel
Perry Brake Robert
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201809050(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TR201809050T4 publication Critical patent/TR201809050T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TR2018/09050T 2013-03-14 2014-03-11 Sızan afinite arındırma ligandının giderilmesi. TR201809050T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
TR201809050T4 true TR201809050T4 (tr) 2018-07-23

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/09050T TR201809050T4 (tr) 2013-03-14 2014-03-11 Sızan afinite arındırma ligandının giderilmesi.

Country Status (17)

Country Link
US (3) US20160024144A1 (enExample)
EP (3) EP4026596A1 (enExample)
JP (1) JP6457479B2 (enExample)
AU (1) AU2014240596B2 (enExample)
CA (1) CA2904411A1 (enExample)
CY (1) CY1120353T1 (enExample)
DK (2) DK2969099T4 (enExample)
ES (2) ES2964601T3 (enExample)
FI (1) FI3395423T3 (enExample)
HU (2) HUE064450T2 (enExample)
LT (2) LT3395423T (enExample)
MX (2) MX365501B (enExample)
PL (2) PL3395423T3 (enExample)
PT (2) PT3395423T (enExample)
SI (2) SI2969099T2 (enExample)
TR (1) TR201809050T4 (enExample)
WO (1) WO2014159441A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3395423T3 (pl) 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
WO2015189832A1 (en) * 2014-06-13 2015-12-17 Lupin Limited Process for the purification of tnfr:fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
WO2017168296A1 (en) * 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
US12516102B1 (en) 2017-02-09 2026-01-06 Bracco Suisse Sa Process for the purification of soluble PSGL-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE204004T1 (de) 1996-06-21 2001-08-15 Merck Patent Gmbh Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0991940B1 (de) 1997-06-18 2010-08-25 Merck Patent GmbH Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP4363986B2 (ja) * 2001-12-21 2009-11-11 イミュネックス・コーポレーション タンパク質の精製方法
BRPI0608584B8 (pt) * 2005-03-11 2021-05-25 Wyeth Corp métodos de recuperar um produto purificado
CN102391358B (zh) * 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
MX2009004974A (es) * 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
CA2932207A1 (en) * 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
US9428546B2 (en) * 2010-07-30 2016-08-30 Pfizer Inc. Tandem purification of proteins
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
PL3395423T3 (pl) 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa

Also Published As

Publication number Publication date
PL2969099T5 (pl) 2022-06-13
WO2014159441A1 (en) 2014-10-02
MX391507B (es) 2025-03-21
DK2969099T4 (da) 2022-03-14
MX2015011994A (es) 2015-12-01
SI2969099T1 (sl) 2018-09-28
HUE038565T2 (hu) 2018-10-29
ES2674697T3 (es) 2018-07-03
LT2969099T (lt) 2018-09-10
US11192919B2 (en) 2021-12-07
US20190085021A1 (en) 2019-03-21
DK2969099T3 (en) 2018-07-09
US20160024144A1 (en) 2016-01-28
PT3395423T (pt) 2023-11-14
FI3395423T3 (fi) 2023-11-02
ES2674697T5 (es) 2022-04-19
JP6457479B2 (ja) 2019-01-23
EP2969099A1 (en) 2016-01-20
JP2016513643A (ja) 2016-05-16
SI2969099T2 (sl) 2022-04-29
US20220144886A1 (en) 2022-05-12
SI3395423T1 (sl) 2023-12-29
HK1220159A1 (en) 2017-04-28
US11492372B2 (en) 2022-11-08
EP4026596A1 (en) 2022-07-13
EP2969099B2 (en) 2021-12-22
AU2014240596B2 (en) 2018-09-27
EP3395423A1 (en) 2018-10-31
HUE064450T2 (hu) 2024-03-28
MX2019006568A (es) 2019-08-22
MX365501B (es) 2019-06-05
PL2969099T3 (pl) 2018-10-31
PT2969099T (pt) 2018-07-05
CA2904411A1 (en) 2014-10-02
PL3395423T3 (pl) 2024-03-18
EP2969099B1 (en) 2018-04-25
AU2014240596A1 (en) 2015-09-24
EP3395423B1 (en) 2023-09-20
DK3395423T3 (da) 2023-11-20
LT3395423T (lt) 2023-12-11
CY1120353T1 (el) 2019-07-10
ES2964601T3 (es) 2024-04-08

Similar Documents

Publication Publication Date Title
US11492372B2 (en) Removal of leaked affinity purification ligand
US9957318B2 (en) Protein purification methods to reduce acidic species
CN102712673B (zh) 用于纯化含fc的蛋白的色谱方法
CA2930350A1 (en) Immunoglobulin purification using pre-cleaning steps
WO2013176754A9 (en) Novel purification of antibodies using hydrophobic interaction chromatography
KR20200019630A (ko) 양이온 교환 크로마토그래피 세척 완충액
CN107849122B (zh) 用低电导率洗涤缓冲液进行亲和层析纯化
KR20210149089A (ko) 사전 포획 응집을 이용하는 것에 의한 면역글로불린의 친화성 크로마토그래피 개선
KR20110139216A (ko) 소형 모듈형 면역약제 단백질의 정제 방법
WO2020172658A1 (en) Methods of isolating a protein
CN114014906A (zh) 一种利用阳离子交换层析纯化疏水性蛋白的方法
Gupta et al. Bioprocess challenges in purification of therapeutic protein charge variants
JP2016519144A (ja) 最小限の単量体の分離を伴う組換えポリクローナル多量体の分離
Capela et al. Monoclonal Antibodies Addressing the Challenges on the Manufacturing Processing of an Advanced Class of Therapeutic Agents
HK40072589A (en) Removal of leaked affinity purification ligand
Akhtar et al. Evaluation of the efficiency of protein A affinity chromatography to purify a monoclonal antibody for cancer treatment and its purity analysis
HK1220159B (en) Removal of leaked affinity purification ligand